CD56+CD3- NK Cells Following Allogeneic Stem Cell Transplantation

Allogeneic Stem Cell Transplant Clinical Trial

Official title: Safety and Toxicity of Escalating Doses of Adoptively Infused ex Vivo Selected CD56+CD3- NK Cells on Day 7 Following Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies.

Status Withdrawn

Clinical Trial Summary

The investigators propose a nonrandomized, Phase I study to assess the safety of infusion of NK cells that will be selected from sibling donors and infused to patients with hematological malignancies early following allogeneic stem cell transplantation.

Clinical Trial Description

Allogeneic hematopoietic stem cell transplantation (HSCT) is a very effective treatment for a number of hematological malignancies but relapse remains a major problem, especially in patients with high risk disease. Natural killer (NK) cells are immune cells that recognize and kill virally infected cells and tumor cells. NK cells are identified by the expression of the CD56 surface antigen and the lack of CD3. Their ability to kill tumor cells makes them promising to evaluate as effector cells for immunotherapy. ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Allogeneic Stem Cell Transplant
• CD56+CD3- NK Cells
• Haematological Malignancies
• Hematologic Neoplasms
• Neoplasms

• NCT number: NCT01336478
• Study type: Interventional
• Source: Imperial College London
• Status: Withdrawn
• Phase: Phase 1
• Start date: April 2011
• Completion date: June 2014